NASDAQ:REPH

Recro Pharma Competitors

$2.76
-0.02 (-0.72 %)
(As of 04/16/2021 04:00 PM ET)
Add
Compare
Today's Range
$2.64
Now: $2.76
$2.80
50-Day Range
$2.54
MA: $3.37
$4.91
52-Week Range
$1.49
Now: $2.76
$9.19
Volume283,435 shs
Average Volume627,547 shs
Market Capitalization$85.60 million
P/E Ratio13.80
Dividend YieldN/A
Beta1.25

Competitors

Recro Pharma (NASDAQ:REPH) Vs. THTX, RDHL, FREQ, HOOK, VRCA, and ONCT

Should you be buying REPH stock or one of its competitors? Companies in the industry of "pharmaceutical preparations" are considered alternatives and competitors to Recro Pharma, including Theratechnologies (THTX), RedHill Biopharma (RDHL), Frequency Therapeutics (FREQ), Hookipa Pharma (HOOK), Verrica Pharmaceuticals (VRCA), and Oncternal Therapeutics (ONCT).

Theratechnologies (NASDAQ:THTX) and Recro Pharma (NASDAQ:REPH) are both small-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their analyst recommendations, profitability, institutional ownership, risk, dividends, valuation and earnings.

Institutional and Insider Ownership

6.3% of Theratechnologies shares are held by institutional investors. Comparatively, 56.3% of Recro Pharma shares are held by institutional investors. 23.1% of Recro Pharma shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Volatility and Risk

Theratechnologies has a beta of 1.79, indicating that its stock price is 79% more volatile than the S&P 500. Comparatively, Recro Pharma has a beta of 1.25, indicating that its stock price is 25% more volatile than the S&P 500.

Analyst Ratings

This is a breakdown of recent ratings and recommmendations for Theratechnologies and Recro Pharma, as reported by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Theratechnologies02302.60
Recro Pharma00203.00

Theratechnologies currently has a consensus price target of $7.1250, suggesting a potential upside of 97.92%. Recro Pharma has a consensus price target of $12.00, suggesting a potential upside of 334.78%. Given Recro Pharma's stronger consensus rating and higher probable upside, analysts plainly believe Recro Pharma is more favorable than Theratechnologies.

Profitability

This table compares Theratechnologies and Recro Pharma's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Theratechnologies-37.22%-135.78%-21.36%
Recro Pharma-34.14%N/A-18.97%

Valuation & Earnings

This table compares Theratechnologies and Recro Pharma's revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Theratechnologies$63.22 million5.34$-12,500,000.00($0.14)-25.71
Recro Pharma$99.22 million0.86$-18,630,000.00$0.2013.80

Theratechnologies has higher earnings, but lower revenue than Recro Pharma. Theratechnologies is trading at a lower price-to-earnings ratio than Recro Pharma, indicating that it is currently the more affordable of the two stocks.

Summary

Recro Pharma beats Theratechnologies on 10 of the 14 factors compared between the two stocks.

RedHill Biopharma (NASDAQ:RDHL) and Recro Pharma (NASDAQ:REPH) are both small-cap medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their dividends, valuation, institutional ownership, analyst recommendations, profitability, risk and earnings.

Risk & Volatility

RedHill Biopharma has a beta of 1.71, indicating that its share price is 71% more volatile than the S&P 500. Comparatively, Recro Pharma has a beta of 1.25, indicating that its share price is 25% more volatile than the S&P 500.

Analyst Recommendations

This is a breakdown of current recommendations and price targets for RedHill Biopharma and Recro Pharma, as provided by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
RedHill Biopharma00303.00
Recro Pharma00203.00

RedHill Biopharma currently has a consensus price target of $20.00, suggesting a potential upside of 181.69%. Recro Pharma has a consensus price target of $12.00, suggesting a potential upside of 334.78%. Given Recro Pharma's higher possible upside, analysts plainly believe Recro Pharma is more favorable than RedHill Biopharma.

Institutional and Insider Ownership

20.4% of RedHill Biopharma shares are held by institutional investors. Comparatively, 56.3% of Recro Pharma shares are held by institutional investors. 23.1% of Recro Pharma shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Profitability

This table compares RedHill Biopharma and Recro Pharma's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
RedHill Biopharma-142.81%-152.19%-45.96%
Recro Pharma-34.14%N/A-18.97%

Earnings and Valuation

This table compares RedHill Biopharma and Recro Pharma's top-line revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
RedHill Biopharma$6.29 million52.37$-42,300,000.00($1.40)-5.07
Recro Pharma$99.22 million0.86$-18,630,000.00$0.2013.80

Recro Pharma has higher revenue and earnings than RedHill Biopharma. RedHill Biopharma is trading at a lower price-to-earnings ratio than Recro Pharma, indicating that it is currently the more affordable of the two stocks.

Summary

Recro Pharma beats RedHill Biopharma on 10 of the 13 factors compared between the two stocks.

Recro Pharma (NASDAQ:REPH) and Frequency Therapeutics (NASDAQ:FREQ) are both small-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their analyst recommendations, dividends, earnings, profitability, institutional ownership, valuation and risk.

Analyst Recommendations

This is a summary of recent ratings and recommmendations for Recro Pharma and Frequency Therapeutics, as reported by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Recro Pharma00203.00
Frequency Therapeutics00303.00

Recro Pharma presently has a consensus target price of $12.00, suggesting a potential upside of 334.78%. Frequency Therapeutics has a consensus target price of $37.00, suggesting a potential upside of 285.82%. Given Recro Pharma's higher probable upside, equities analysts clearly believe Recro Pharma is more favorable than Frequency Therapeutics.

Institutional & Insider Ownership

56.3% of Recro Pharma shares are held by institutional investors. Comparatively, 57.5% of Frequency Therapeutics shares are held by institutional investors. 23.1% of Recro Pharma shares are held by insiders. Comparatively, 15.4% of Frequency Therapeutics shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Profitability

This table compares Recro Pharma and Frequency Therapeutics' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Recro Pharma-34.14%N/A-18.97%
Frequency Therapeutics-68.59%-12.56%-9.92%

Volatility and Risk

Recro Pharma has a beta of 1.25, indicating that its share price is 25% more volatile than the S&P 500. Comparatively, Frequency Therapeutics has a beta of 0.69, indicating that its share price is 31% less volatile than the S&P 500.

Earnings & Valuation

This table compares Recro Pharma and Frequency Therapeutics' revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Recro Pharma$99.22 million0.86$-18,630,000.00$0.2013.80
Frequency Therapeutics$28.95 million11.32$-18,750,000.00($2.29)-4.19

Recro Pharma has higher revenue and earnings than Frequency Therapeutics. Frequency Therapeutics is trading at a lower price-to-earnings ratio than Recro Pharma, indicating that it is currently the more affordable of the two stocks.

Summary

Recro Pharma beats Frequency Therapeutics on 9 of the 13 factors compared between the two stocks.

Recro Pharma (NASDAQ:REPH) and Hookipa Pharma (NASDAQ:HOOK) are both small-cap medical companies, but which is the superior investment? We will compare the two companies based on the strength of their profitability, earnings, valuation, analyst recommendations, risk, institutional ownership and dividends.

Earnings and Valuation

This table compares Recro Pharma and Hookipa Pharma's revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Recro Pharma$99.22 million0.86$-18,630,000.00$0.2013.80
Hookipa Pharma$11.94 million27.28$-43,040,000.00($2.41)-5.20

Recro Pharma has higher revenue and earnings than Hookipa Pharma. Hookipa Pharma is trading at a lower price-to-earnings ratio than Recro Pharma, indicating that it is currently the more affordable of the two stocks.

Analyst Ratings

This is a summary of recent ratings and price targets for Recro Pharma and Hookipa Pharma, as reported by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Recro Pharma00203.00
Hookipa Pharma00703.00

Recro Pharma currently has a consensus target price of $12.00, indicating a potential upside of 334.78%. Hookipa Pharma has a consensus target price of $21.1429, indicating a potential upside of 68.60%. Given Recro Pharma's higher probable upside, equities research analysts plainly believe Recro Pharma is more favorable than Hookipa Pharma.

Profitability

This table compares Recro Pharma and Hookipa Pharma's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Recro Pharma-34.14%N/A-18.97%
Hookipa Pharma-232.00%-39.58%-31.33%

Institutional & Insider Ownership

56.3% of Recro Pharma shares are owned by institutional investors. Comparatively, 33.4% of Hookipa Pharma shares are owned by institutional investors. 23.1% of Recro Pharma shares are owned by company insiders. Comparatively, 4.0% of Hookipa Pharma shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Volatility & Risk

Recro Pharma has a beta of 1.25, meaning that its stock price is 25% more volatile than the S&P 500. Comparatively, Hookipa Pharma has a beta of 1.18, meaning that its stock price is 18% more volatile than the S&P 500.

Summary

Recro Pharma beats Hookipa Pharma on 11 of the 13 factors compared between the two stocks.

Recro Pharma (NASDAQ:REPH) and Verrica Pharmaceuticals (NASDAQ:VRCA) are both small-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their profitability, valuation, dividends, earnings, risk, analyst recommendations and institutional ownership.

Institutional and Insider Ownership

56.3% of Recro Pharma shares are held by institutional investors. Comparatively, 34.0% of Verrica Pharmaceuticals shares are held by institutional investors. 23.1% of Recro Pharma shares are held by insiders. Comparatively, 40.2% of Verrica Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Profitability

This table compares Recro Pharma and Verrica Pharmaceuticals' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Recro Pharma-34.14%N/A-18.97%
Verrica PharmaceuticalsN/A-54.53%-40.42%

Analyst Recommendations

This is a summary of recent ratings and recommmendations for Recro Pharma and Verrica Pharmaceuticals, as reported by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Recro Pharma00203.00
Verrica Pharmaceuticals01302.75

Recro Pharma currently has a consensus target price of $12.00, suggesting a potential upside of 334.78%. Verrica Pharmaceuticals has a consensus target price of $17.75, suggesting a potential upside of 39.87%. Given Recro Pharma's stronger consensus rating and higher probable upside, research analysts clearly believe Recro Pharma is more favorable than Verrica Pharmaceuticals.

Volatility & Risk

Recro Pharma has a beta of 1.25, meaning that its share price is 25% more volatile than the S&P 500. Comparatively, Verrica Pharmaceuticals has a beta of 2.3, meaning that its share price is 130% more volatile than the S&P 500.

Earnings & Valuation

This table compares Recro Pharma and Verrica Pharmaceuticals' top-line revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Recro Pharma$99.22 million0.86$-18,630,000.00$0.2013.80
Verrica PharmaceuticalsN/AN/A$-28,210,000.00($1.13)-11.23

Recro Pharma has higher revenue and earnings than Verrica Pharmaceuticals. Verrica Pharmaceuticals is trading at a lower price-to-earnings ratio than Recro Pharma, indicating that it is currently the more affordable of the two stocks.

Summary

Recro Pharma beats Verrica Pharmaceuticals on 9 of the 13 factors compared between the two stocks.

Recro Pharma (NASDAQ:REPH) and Oncternal Therapeutics (NASDAQ:ONCT) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their earnings, risk, profitability, valuation, analyst recommendations, dividends and institutional ownership.

Institutional and Insider Ownership

56.3% of Recro Pharma shares are held by institutional investors. Comparatively, 10.8% of Oncternal Therapeutics shares are held by institutional investors. 23.1% of Recro Pharma shares are held by company insiders. Comparatively, 10.9% of Oncternal Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Earnings & Valuation

This table compares Recro Pharma and Oncternal Therapeutics' top-line revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Recro Pharma$99.22 million0.86$-18,630,000.00$0.2013.80
Oncternal Therapeutics$2.42 million132.18$-34,190,000.00($1.56)-4.15

Recro Pharma has higher revenue and earnings than Oncternal Therapeutics. Oncternal Therapeutics is trading at a lower price-to-earnings ratio than Recro Pharma, indicating that it is currently the more affordable of the two stocks.

Risk & Volatility

Recro Pharma has a beta of 1.25, indicating that its stock price is 25% more volatile than the S&P 500. Comparatively, Oncternal Therapeutics has a beta of 1.66, indicating that its stock price is 66% more volatile than the S&P 500.

Profitability

This table compares Recro Pharma and Oncternal Therapeutics' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Recro Pharma-34.14%N/A-18.97%
Oncternal Therapeutics-746.10%-150.58%-91.87%

Analyst Ratings

This is a summary of current recommendations for Recro Pharma and Oncternal Therapeutics, as reported by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Recro Pharma00203.00
Oncternal Therapeutics00503.00

Recro Pharma presently has a consensus target price of $12.00, suggesting a potential upside of 334.78%. Oncternal Therapeutics has a consensus target price of $15.20, suggesting a potential upside of 134.57%. Given Recro Pharma's higher possible upside, analysts plainly believe Recro Pharma is more favorable than Oncternal Therapeutics.

Summary

Recro Pharma beats Oncternal Therapeutics on 10 of the 13 factors compared between the two stocks.


Recro Pharma Competitors List

Competitor NameCompetitor BTM RankCompetitor PriceCompetitor Price ChangeCompetitor Market CapCompetitor RevenueCompetitor P/E RatioCompetitor Indicator(s)
Theratechnologies logo
THTX
Theratechnologies
1.1$3.60-0.0%$337.83 million$63.22 million-11.61Earnings Announcement
RedHill Biopharma logo
RDHL
RedHill Biopharma
1.4$7.10-3.9%$329.40 million$6.29 million-4.08Gap Down
Frequency Therapeutics logo
FREQ
Frequency Therapeutics
1.5$9.59-2.2%$327.77 million$28.95 million-13.70Increase in Short Interest
Hookipa Pharma logo
HOOK
Hookipa Pharma
1.2$12.54-0.9%$325.66 million$11.94 million-7.65Analyst Report
Analyst Revision
News Coverage
Verrica Pharmaceuticals logo
VRCA
Verrica Pharmaceuticals
1.6$12.69-7.9%$322.85 millionN/A-9.61Analyst Report
Oncternal Therapeutics logo
ONCT
Oncternal Therapeutics
1.7$6.48-5.4%$319.88 million$2.42 million-5.68Analyst Report
Gap Up
Tonix Pharmaceuticals logo
TNXP
Tonix Pharmaceuticals
1.8$0.98-6.1%$317.44 millionN/A-0.28Increase in Short Interest
Gap Up
Wave Life Sciences logo
WVE
Wave Life Sciences
1.8$6.27-1.1%$307.21 million$15.98 million-1.11Decrease in Short Interest
News Coverage
ProQR Therapeutics logo
PRQR
ProQR Therapeutics
1.4$6.00-3.0%$301.23 millionN/A-4.88Increase in Short Interest
Immunic logo
IMUX
Immunic
1.8$14.21-8.7%$300.80 millionN/A-4.82Analyst Report
Increase in Short Interest
News Coverage
Gap Down
Trevena logo
TRVN
Trevena
1.3$1.86-21.0%$299.97 million$30,000.00-8.09High Trading Volume
News Coverage
Gap Up
CymaBay Therapeutics logo
CBAY
CymaBay Therapeutics
1.6$4.32-0.0%$297.85 millionN/A-4.60
Arbutus Biopharma logo
ABUS
Arbutus Biopharma
1.4$3.07-4.2%$295.75 million$6.01 million-2.50Gap Down
VistaGen Therapeutics logo
VTGN
VistaGen Therapeutics
1.3$2.05-2.9%$293.85 millionN/A-4.27Analyst Upgrade
Decrease in Short Interest
News Coverage
Sol-Gel Technologies logo
SLGL
Sol-Gel Technologies
1.2$14.36-2.4%$292.80 million$22.90 million-10.80
TFF Pharmaceuticals logo
TFFP
TFF Pharmaceuticals
1.4$12.07-0.5%$279.30 millionN/A-4.57Increase in Short Interest
Kezar Life Sciences logo
KZR
Kezar Life Sciences
1.3$5.74-3.7%$275.90 millionN/A-4.59News Coverage
Gap Down
Kamada logo
KMDA
Kamada
1.4$6.17-2.6%$274.69 million$127.19 million12.85News Coverage
Gap Down
VYNE Therapeutics logo
VYNE
VYNE Therapeutics
1.8$5.35-2.2%$274.35 million$10.64 million-1.43
Infinity Pharmaceuticals logo
INFI
Infinity Pharmaceuticals
1.6$2.98-3.4%$264.15 million$3.05 million-4.20Analyst Upgrade
Gap Down
Alpine Immune Sciences logo
ALPN
Alpine Immune Sciences
1.8$11.00-2.5%$262.70 million$1.74 million-7.64Insider Selling
News Coverage
NextCure logo
NXTC
NextCure
1.6$9.42-0.5%$259.99 million$6.35 million-8.34
Mustang Bio logo
MBIO
Mustang Bio
1.6$3.05-3.9%$259.78 millionN/A-2.44Increase in Short Interest
Gap Down
Immunome logo
IMNM
Immunome
1.0$24.06-9.3%$256.48 millionN/A0.00Analyst Upgrade
Gap Down
TLC
Taiwan Liposome
1.2$5.99-4.8%$252.04 million$6.99 million-7.49Gap Down
Ovid Therapeutics logo
OVID
Ovid Therapeutics
1.5$3.78-1.1%$248.55 millionN/A-2.68Analyst Downgrade
Decrease in Short Interest
News Coverage
Oramed Pharmaceuticals logo
ORMP
Oramed Pharmaceuticals
1.3$8.45-3.9%$248.18 million$2.71 million-14.57Earnings Announcement
Gap Down
9 Meters Biopharma logo
NMTR
9 Meters Biopharma
1.8$1.10-1.8%$237.68 millionN/A0.00
Tricida logo
TCDA
Tricida
1.9$4.68-9.0%$235.14 millionN/A-0.87Analyst Downgrade
News Coverage
Gap Down
Xeris Pharmaceuticals logo
XERS
Xeris Pharmaceuticals
1.6$3.91-1.3%$233.68 million$2.72 million-0.98Increase in Short Interest
PLx Pharma logo
PLXP
PLx Pharma
1.5$10.61-1.1%$231.16 million$570,000.00-8.63Analyst Upgrade
News Coverage
Gap Down
Mereo BioPharma Group logo
MREO
Mereo BioPharma Group
1.4$3.35-0.6%$227.10 millionN/A-1.35Analyst Downgrade
Increase in Short Interest
News Coverage
Cerecor logo
CERC
Cerecor
1.8$2.51-3.6%$223.65 million$6.75 million-8.37Gap Down
vTv Therapeutics logo
VTVT
vTv Therapeutics
1.2$2.71-8.1%$218.60 million$2.76 million-6.16Gap Down
MediciNova logo
MNOV
MediciNova
1.2$4.49-3.6%$218.58 millionN/A0.00Upcoming Earnings
News Coverage
Citius Pharmaceuticals logo
CTXR
Citius Pharmaceuticals
1.3$1.73-1.2%$217.61 millionN/A0.00Increase in Short Interest
News Coverage
Corbus Pharmaceuticals logo
CRBP
Corbus Pharmaceuticals
1.7$1.72-2.3%$215.06 million$36.14 million-0.96News Coverage
Checkpoint Therapeutics logo
CKPT
Checkpoint Therapeutics
1.2$2.85-4.2%$214.35 million$1.71 million-6.20News Coverage
Immutep logo
IMMP
Immutep
1.3$3.29-2.4%$213.43 million$4.92 million0.00Increase in Short Interest
Medicenna Therapeutics logo
MDNA
Medicenna Therapeutics
0.7$3.97-0.0%$210.23 millionN/A-19.85Increase in Short Interest
Analyst Revision
Sierra Oncology logo
SRRA
Sierra Oncology
1.8$17.93-2.6%$208.49 millionN/A-1.28Increase in Short Interest
Gap Down
NuCana logo
NCNA
NuCana
1.5$4.29-1.2%$208.04 millionN/A-4.25
Harrow Health logo
HROW
Harrow Health
1.4$8.00-8.8%$207.86 million$51.17 million-100.00High Trading Volume
News Coverage
Osmotica Pharmaceuticals logo
OSMT
Osmotica Pharmaceuticals
1.1$3.27-3.7%$204.65 million$240.03 million-3.55Gap Up
Anchiano Therapeutics logo
ANCN
Anchiano Therapeutics
0.8$27.26-23.2%$202.27 millionN/A181.73Gap Down
Kindred Biosciences logo
KIN
Kindred Biosciences
1.6$4.85-2.5%$201.03 million$4.26 million-7.03
Tyme Technologies logo
TYME
Tyme Technologies
1.3$1.53-0.7%$199.55 millionN/A-6.95
Neptune Wellness Solutions logo
NEPT
Neptune Wellness Solutions
1.3$1.20-2.5%$198.66 million$22.05 million-2.40
Eton Pharmaceuticals logo
ETON
Eton Pharmaceuticals
1.3$8.08-5.9%$197.22 million$460,000.00-6.79News Coverage
Lannett logo
LCI
Lannett
2.0$4.76-0.2%$197.07 million$545.74 million-6.61
This page was last updated on 4/18/2021 by MarketBeat.com Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security. Learn more.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.